Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mifepristone 600 mg daily Clear all
Terminated Phase 2 Interventional Results available

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Mifepristone for the Prevention of Relapses of Alcohol Drinking

NCT02243709
View directory record Official record
Conditions
Alcohol Use Disorders (AUD)
Interventions
Mifepristone 600-mg/day or placebo for a week
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 3 Interventional

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00128479
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
44
States / cities
Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 3, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Mifepristone 600 mg daily, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

NCT03258372
View directory record Official record
Conditions
Healthy
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 3, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

NCT04588688
View directory record Official record
Conditions
Central Adrenal Insufficiency, Mifepristone
Interventions
Mifepristone
Drug
Lead sponsor
Tobias Else
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 3, 2026, 8:19 PM EDT
Not listed Phase 2 Interventional

Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder

NCT00833339
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
mifepristone, placebo
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

NCT01548417
View directory record Official record
Conditions
Alcoholism
Interventions
Korlym (mifepristone), Sugar Pill
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 3 Interventional

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00130676
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
Mifepristone, matching placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Pico Rivera, California • Riverside, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 3, 2026, 8:19 PM EDT
Terminated Early Phase 1 Interventional

Glucocorticoid Antagonist Treatment for Tobacco Use Disorder

NCT03248713
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone

NCT01739335
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Mifepristone Oral Tablet [Korlym], Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
San Diego, California • Albuquerque, New Mexico • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169
View directory record Official record
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym], Placebo for mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Escondido, California • Gardena, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 3, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

NCT01493310
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, placebo, nab-paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 3, 2026, 8:19 PM EDT